anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
232,089. Rosher, F. N. D. July 30, 1924. Light and other radiations, treating diseases with.-A bandage, pad, or the like carrying or embodying radioactive material is constructed in the form of a frame-like body so that only the healthy tissue surrounding the affected part is acted on by the radiations. The bandage &amp;c. may be suitably covered to avoid exposure of the affected part. For example, radioactive material may be applied to annular corn-plasters, which are constructed so that the radiations act on the unaffected tissue at the margin of the corn. The radioactive material may be replaced or supplemented by substances, such as zinc sulphide, capable of emitting radiations after excitation by light.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide granules extremely facilitating the molding of calcium carbonate, and to provide a method for preparing the granules.  &lt;P&gt;SOLUTION: The granular composition includes the calcium carbonate having a small median particle diameter (0.1-20 μm). The extremely moldable calcium carbonate granules are formed by mixing a composition containing the calcium carbonate in a mixer providing high shear, and drying the resultant composition in a convection drier. The improvement of moldability is achieved further by using a preparation containing the powdery composition having the smaller median particle diameter. Further improvement is achieved by using a preparation containing two or more kinds of powdery compositions having different median particle diameters. The granules are useful for the tableting of a medicine and a functional food, and provide a tablet having a size smaller than that of the conventionally available one.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
This invention is mainly about the making of wounds on the Aquilaria&#39;s trunk in order to stimulate the process of Aquilaria resin formation. The wounds in this invention include details of wounds made on the Aquilaria&#39;s trunk with the specifications of shape, location, size, beveling, gouging, making holes, and the method of leading the stimulant to Aquilaria through the wounds. The details are shown in this invention. The methods begin with the selection of Aquilaria trees, which have a diameter of about 50 centimeters. Then make a square shaped wound on the trunk with the size and position as specified in the details of the invention. The rims will be gouged as the small channel. Inside the square, make many holes deep into the heartwood. These holes will stimulate Aquilaria to release resin and it is easier to use the stimulant to merge the wounds. In proper time, the resin can be collected and used for further benefits.
The present disclosure relates to a method of identifying a region of interest in a stained tissue image. Graph-theoretic segmentation methods for segmenting histological structures in H &amp; E stained tissue images. The method relies on characterizing local spatial statistics in the image. Furthermore, the methods for quantifying intratumoral spatial heterogeneity can be used with single biomarker, multiplexed or supercomplex Immunofluorescence (IF) data. The method is holistic in its way, using the expression and spatial information of whole tumor tissue sections and/or spots in TMAs to characterize spatial correlations. The method generates a two-dimensional heterogeneity map to clearly elucidate the spatial associations of the major and minor subpopulations.
FIELD: medicine. SUBSTANCE: this method prescribes sampling cerebrospinal fluid batchwise (5 to 10 ml) in total amount of 2 to 3 ml per 1 kg of patient&#39;s mass, purifying sampled cerebrospinal fluid using activated fibrous material having total benzol pore volume of more than 0.29 cu. cm/g, ratio between volume of micropores and transient pores ranging from 1.3 to 2.3 units, and finally reinjecting purified fluid into cerebrospinal canal. Disclosed method further prescribes using purpose-designed syringe characterized by specific constructional traits that allow expanding its functional capabilities. Syringe incorporates two interconnected bodies, rods and pistons. Subpiston space of first body houses adsorption member compressed by piston. Piston and rod housed in first body have through opening via which subpiston space of first body communicates with subpiston space of second one. Amount of cerebrospinal fluid can be checked by referring to scale marked on second body. EFFECT: disclosed method permits enhancing effectiveness of traditional methods of intensive medicamentous therapy; lower rate of fatal outcomes. 2 cl, 2 dwg, 4 tbl
The System and Method for Developing a Customized Wetness Plan of the present invention provides a means of measuring a user&#39;s wellness by determining a user&#39;s physiological age. The disclosed system and method also provides a means by which a user can learn about personalized wellness options, where the wellness options have been chosen for the user based upon wellness factors input by the user, additional constraints input by the user and the most recently available information relating to the health sciences. The user can select one or more of the disclosed options, and determine the potential effect implementing the options could have on the user&#39;s physiological age over the short or long term. In this fashion, the user can continue selecting various groups of alternatives until he or she has determined the group of options that the user would like to implement as a wellness plan. The user can then obtain further information regarding the chosen wellness plan from the system and method of the present invention. The disclosed system and method also provides a means whereby a user can monitor their progress toward improving wellness, wherein this progress can be positive or negative.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a tyrosinase inhibitor which is obtained from a natural raw material, inhibits the activity of the tyrosinase to suppress the production of melamine, little produces side effects, and is useful as a bleaching ingredient, and to provide a new external preparation for skins, which contains an ingredient obtained from a natural raw material, has a tyrosinase-inhibiting function, and is useful as a cosmetic and the like.  &lt;P&gt;SOLUTION: This tyrosinase inhibitor is characterized by containing as an active ingredient a black soybean skin extract composition extracted from black soybean skins. The external preparation for skins is characterized by containing as an active ingredient a black soybean skin extract composition extracted from black soybean skins. The black soybean skin extract composition is a composition obtained by extracting the black soybean skins with acidic water, and then subjecting the extract to a concentration treatment, a neutralization treatment and a desalting and concentration treatment using an ultrafiltration membrane. It has experimentally been confirmed that the water-soluble ingredient eluted by the water extraction of the black soybean skins exhibits the tyrosinase-inhibiting effect. The tyrosinase inhibitor and the external preparation for skins, which contain the black soybean skin extract compositions as the active ingredients, exhibit good bleaching actions, respectively.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
PURPOSE:To provide a cosmetic having excellent safety and stability and containing a colorant consisting of fine chromium oxide pigment completely free from Cr&lt;6+&gt; ion. CONSTITUTION:The objective cosmetic is produced by using a colorant consisting of fine powder of chromium oxide pigment having an average particle diameter of 0.1 to 2mum, containing &lt;=2wt.% of coarse particles of &gt;=5mum diameter and completely free from Cr&lt;6+&gt; ion and compounding the colorant to conventional cosmetic components. The fine chromium oxide pigment is the one treated with an organic reducing agent safe to the skin (e.g. ascorbic acid, especially L-ascorbic acid, etc.) and, as necessary, having a surface converted to hydrophobic with an organic silicate compound, higher fatty acid, etc. The hydrophobic treatment is effective in further improving the dispersibility and stability.
FIELD: medicine, pharmacy. SUBSTANCE: composition comprises the modified plasminogen activator of urokinase type mAPUT22 with specific activity 80 000-100 000 IU/mg of enzyme as an active substance that shows the definite amino acid sequence consisting of 403 amino acids and taken in the effective therapeutic dose and excipient also. Composition contains dextran with molecular mass 10 000-70 000 Da and sodium chloride as excipients. Composition can be used in ophthalmology. The novel composition shows the enhanced specific fibrinolytic and thrombolytic activity, it doesn&#39;t cause danger adverse effects in treatment of intraocular hemorrhages and fibrinous exudates arising in traumas and inflammatory diseases of eyes. EFFECT: enhanced effectiveness and valuable medicinal properties of composition. 5 cl
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a crystalline organic salt of amlodipine, used as an antihypertensive having calcium channel blocking activity.  &lt;P&gt;SOLUTION: This new crystalline organic salt of the amlodipine having excellent physicochemical characteristics, a method for producing the same, and a pharmaceutical composition containing the same are provided, respectively. Crystalline amlodipine adipate has the excellent physicochemical characteristics (nonhygroscopicity, stability, solubility, and processability) and has, especially, excellent light stability. Therefore, the crystalline amlodipine adipate is easily carried by a patient and stored for a long period. Further, the amlodipine adipate is industrially advantageous, because adipic acid exhibits no corrosivity, nor harmfulness, nor moisture absorption and, therefore, is easily handled, when compared with benzenesulfonic acid which is used in producing amlodipine besylate.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a preparation capable of readily being taken into the body by making it small-size without lowering medicinal benefits and a preparation improved in its solubility, in a therapeutic medicine for hyperlipemia in which a composition of fenofibrate with polyethylene glycol is formulated.  &lt;P&gt;SOLUTION: The solid dispersion is prepared by melt-mixing fenofibrate with polyethylene glycol and solidifying the mixture. In the solid dispersion, the ratio of fenofibrate to the solid dispersion is ≥50 mass%. A capsule or a tablet comprises the solid dispersion. The capsule is obtained by mixing the solid dispersion with a crystalline cellulose and packing the mixture into a capsule or the capsule is obtained by mixing the solid dispersion with the crystalline cellulose, sodium lauryl sulfate and magnesium stearate and packing the mixture into a capsule. The therapeutic agent for hyperlipemia comprises the solid dispersion as an active ingredient.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE:To obtain water-repellent powders which have surfaces having improved wettability and improved penetrability and are uniformly coated in a short time, by mixing a powder with a treating soln. composed of a fluorohydrocarbon contg. a water-repelling agent and removing the fluorohydrocarbon. CONSTITUTION:A powder is mixed with a treating soln. composed of a fluorohydrocarbon contg. a water-repelling agent and having a surface tension of 20dyn.cm&lt;-1&gt; under pressure and/or under low temp. conditions. The fluorohydrocarbon is removed from the mixture under atmospheric pressure and/or under elevated temp. conditions to coat uniformly the surface of the powder with the water-repelling agent. If desired, a baking treatment is carried out at a high temp. to obtain the desired powder. Preferred examples of the water-repelling agents are methylhydrogenpolysiloxane, dimethylpolysiloxane, methylphenylpolysiloxane and mixtures thereof from the viewpoints of compati bility with the fluorohydrocarbon, the degree of water repellency of the resulting water-repellent powder and organoleptic properties such as touch feeling.
PROBLEM TO BE SOLVED: To obtain the subject compound providing an optically active benzothiepine derivative in high purity and in high yield useful as a raw material compound for a preventive and a therapeutic agent for bone diseases, by reacting a specific benzothiepine derivative with an optically active amine. SOLUTION: A benzothiepine derivative of formula I (R is a lower alkyl) is reacted with an optically active amine. The reaction is preferably carried out by using 0.5-1.0 equivalent of the optically active amine based on the compound of formula I, blending and reacting both the compounds in methanol or tetrahydrofuran and crystallizing or recrystallizing the objective compound. The reaction temperature is 0-30 deg.C and the reaction time is preferably 1-10 hours. A compound of formula II (R&lt;1&gt; is a phenyl which may be replaced; R&lt;2&gt; to R&lt;4&gt; are each H or a lower alkyl; R&lt;5&gt; is H, OH, etc.), especially (1R,2S)- norephedrine is preferable as the optically active amine. The objective compound is deaminated to give an optically active benzothiepine derivative.
PROBLEM TO BE SOLVED: To obtain a bathing composition capable of improving slippery feeling of the skin, capable of securing moist feeling of the skin after bathing, and hardly allowing various germs to propagate even if the solution is left after the bathing by using alkaline inorganic salts except boric acid compound, in combination with the boric acid compound and a cationized polymer. SOLUTION: This bathing composition consists essentially of a boric acid compound [preferably, e.g. borax (Na2B4O7.10H2O), and at 20-70 wt.% based on the alkaline inorganic salts], and the alkaline inorganic salts (e.g. sodium carbonate) except the boric acid compound. The content of the inorganic salts based on the solution using the composition is preferably &gt;=40 wt.% so that the pH may be alkaline of 8.0-11. A cationized polymer (e.g. a cationized cellulose) is preferably included at 0.1-20 wt.% based on the total amount of the inorganic salts and the cationized polymer.
&lt;P&gt;PROBLEM TO BE SOLVED: To realize useful data management for assisting analysis and treatment.  &lt;P&gt;SOLUTION: Method and clinical analysis system are provided to realize data management for assisting the analysis and treatment. The clinical analysis system includes a biosensor for receiving and processing a user specimen, and a memory as means for storing two or more patient records including a designated parameter data value. A processor device is connected to the biosensor for receiving and processing two or more patient records and creating a report. A fax drive mechanism connected to the processor device transmits the created report through a telephone network to a designated fax machine in a clinic.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
Pharmaceutical compsns. for admin. intranasally, such as a liquid nasal spray, contain a calcitonin (I), a benzalkonium chloride and a suitable liquid diluent or carrier. (I) is derived from fish, esp. salmon or eels, humans, or pigs. That derived from salmon is preferred. The preferred concentration of the benzalkonium chloride is 0.003-0.03% w/v. Other materials that may be present include surfactants, preservatives, oiliary stimulants and pH regulators. The unit dose of (I) is 50-400 MRC units, given at a rate between once per day and 3 times per week. The total volume given per admin. is pref. between 0.05 and 0.15 ml. (I) is known for the treatment of Paget&#39;s disease, hypercalcaemia, and osteoporosis. Previously, (I) needed to be administered by injection, usually intramuscularly. This was painful and inconvenient since regular administration is necessary. The present compositions allow self-medication to take place.
1,193,829. Liquid cosmetic compositions. J. H. MARCARIAN and R. L. J. CLEMENCET. 6 June, 1967 [17 June, 1966], No. 26132/67. Heading A5B. Liquid cosmetic compositions are prepared by mixing a finely crushed (as defined) pigment with a high molecular weight (as defined) organic polymer in ethanol, the dispersion being stabilized by an oxyethylenated fatty alcohol, adding a polyol of low molecular weight (as defined) in aqueous solution to the colloidal mass obtained and then adding a aqueous solution of a cationic surface active agent to the suspension (which is kept in movement), the composition containing 5-20 parts by weight of pigment 2-10 parts by weight of oxyethylenated fatty alcohol, 0.1-5 parts by weight of high molecular weight polymer in colloidal solution, 2-20 parts by weight of polyol, 1-5 parts by weight of surface active agent and distilled water or water/ethanol to 100 parts &#39;by weight. The high molecular weight polymer is suitably polyvinylpyrrolidone or a copolymerisate of polyvinylpyrrolidone and vinyl acetate. The low molecular weight polyol is suitably propylene glycol.
PROBLEM TO BE SOLVED: To obtain the subject therapeutic medicine effective for the therapy of vertebra damages, especially traumatic vertebra damages, by including a specific compound (acid adduct) as an active ingredient. SOLUTION: This therapeutic medicine is obtained by mixing (A) a compound (acid adduct) of the formula (R&lt;1&gt; is H, OH) with (B), if necessary, a carrier such as gelatin, a saccharide or starch or a liquid carrier such as water, physiological salt solution or a sugar solution and subsequently preparing the mixture into the preparation suitable for the administration. When the mixture is prepared into capsules, gelatin, etc., is preferably used. The ingredient A is preferably contained in an amount of 0.01-80wt.% in the therapeutic agent. The administration method includes oral administration and parenteral administration. The therapeutic agent is administered at a daily dose of 0.01-20mg/kg on the parenteral administration and at a daily dose of 0.02-40mg/kg on the oral administration.
PURPOSE:To provide an antitrichophytic agent containing an alkyldimethylamine tetraborate as an active component, exhibiting antifungal activity against tricophytons, usable without generating resistant trichophyton and suitable for the clinical remedy for athlete&#39;s foot. CONSTITUTION:The compound of formula (R is 10-14C alkyl) or its hydrate is used as an active component of the objective agent. It can be used in the form of an ointment by using liquid paraffin, petrolatum, etc., as a base or a liquid agent by using a mixture of ethanol and water as a base. The ratio of the active compound of formula in the preparation is 0.1-100wt.% preferably 0.5-10wt.%. The compound of formula can be synthesized e.g. by reacting octyldimethylamine with metaboric acid at 140-170 deg.C, preferably 140-150 deg.C.
PURPOSE: To express a gene coding desired antigen in a liver cell and produce a monoclonal antibody by introducing the gene into an initial culture liver cell of an animal by &#39;Lipofectin(R)&#39;. CONSTITUTION: A complex of a cationic liposome with a gene coding a desired antigen is formed and the complex is introduced into an initial cultured liver cell of an animal. The cationic liposome is bound to the circumference of DNA having a negative charge and forms an artificial lipid double layer. Besides, since the cell has negative charge and readily can take positive charge therein and an unit membrane forms the lipid double layer, the cell fuses with the cationic liposome. The resultant liver cell immunizes a same kind of animal as the derived animal. Immunizing operation is carried out by subjecting a suspension of the liver cell into intraperitoneal or intravenous administration.
The invention relates to a traditional Chinese medical instrumentation, in particular to a Sang-Fu-Teh acupoint pasting film which is simply and conveniently used. In the invention, different traditional Chinese medical ointment can be selected according to diseases to be treated and then applied to a drug storage tank of the pasting film so as to facilitate medical personnel to carry out acupoint application for treating the diseases. The Sang-Fu-Teh acupoint pasting film can facilitate drug replacement in acupoint application, improve working efficiency of Sang-Fu-Teh plaster, reduce working strength and working load of the medical personnel and shorten waiting time of a patient. The Sang-Fu-Teh acupoint pasting film is composed of medical rubber adhesive plaster, the drug storage tank and a covering film; and only the traditional Chinese medical ointment is added to the drug storage tank when in use and then applied to a corresponding acupoint. The Sang-Fu-The acupoint pasting film is used in a Sang-Fu-Teh therapy of the traditional Chinese medical characteristic therapy &#39;winter disease being cured in summer&#39; and the traditional Chinese medical external therapy such as the Sang-Fu-Teh therapy, common acupoint application and the like. The Sang-Giu-Teh acupoint pasting film has the advantages of convenient use, being safe and reliable, saved time of an operator, low manufacturing cost and easy popularization and application.
GABA-related pro-drugs of the formula (III) are provided that when administered to humans or other mammals provide an increased duration of active compound in the plasma compared to compounds of corresponding structure in which labile groups are not present. The compounds are of the formula (III)In the above formula:P represents hydrogen or methyl;Q represents a labile amine- or amide-forming organic group that becomes removed in the human or animal body;R&lt;1 &gt;represents straight or branched C2-C6 alkyl, C3-C6 cycloalkyl or phenyl;R&lt;2 &gt;represents hydrogen or methyl; andR&lt;3 &gt;represents hydrogen, methyl or carboxyl; andR&lt;4 &gt;represents hydrogen or a labile ester-forming group selected from substituted and unsubstituted C1-C6 alkyl, benzyl and phenyl groups that become removed in the human or animal body. In the above formula when R&lt;1 &gt;is phenyl, R&lt;2&gt;, R&lt;3 &gt;and R&lt;4 &gt;are not simultaneously hydrogen. Pharmaceutically acceptable salts of any salt-forming compound within the above class are also included. The compounds may be used to treat a range of neurological conditions, e.g. epilepsy and pain.
The invention provides an isolated nucleic acid encoding the rat P450 2C11 arachidonic acid epoxygenase, or a human homologue thereof, having a mutation associated with salt induced hypertension. Also provided is an isolated cell line expressing the epoxygenase encoded by the mutated nucleic acid, and a non-human transgenic animal having a germ line insertion of the mutated nucleic acid. Also provided is a method of screening a compound for efficacy in treating salt induced hypertension comprising administering the compound to such a non-human transgenic animal, and detecting an improvement in the animal&#39;s hypertension. The invention also provides a method of screening a human subject for a genetic predisposition to salt induced hypertension comprising detecting a mutation in a human homologue of a rat P450 2C11 arachidonic acid epoxygenase gene which affects normal epoxygenase activity. Also provided is a method of treating salt induced hypertension in a human subject associated with a genetic mutation in a human homologue of the rat P450 2C11 arachidonic acid epoxygenase gene, comprising administering to the subject a functional metabolite, or analogue thereof, produced by the human homologue of the rat P450 2C11 arachidonic acid epoxygenase. Also provided is an isolated mutated rat P450 2C11 arachidonic acid epoxygenase, or a human homologue thereof, having a mutation associated with salt induced hypertension.